FY2025 EPS Estimate for Puma Biotechnology Lifted by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Analysts at Zacks Research raised their FY2025 earnings per share estimates for shares of Puma Biotechnology in a research note issued to investors on Thursday, January 9th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings per share of $0.28 for the year, up from their prior forecast of $0.26. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology's Q2 2026 earnings at $0.06 EPS.

A number of other research analysts have also commented on the company. HC Wainwright reiterated a "buy" rating and set a $7.00 price target on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com cut Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Friday, December 6th.

Puma Biotechnology Stock Performance

Shares of NASDAQ:PBYI traded down $0.24 during trading on Friday, reaching $3.31. The stock had a trading volume of 799,584 shares, compared to its average volume of 1,230,901. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a 52 week low of $2.22 and a 52 week high of $7.73. The stock has a fifty day simple moving average of $3.05 and a two-hundred day simple moving average of $2.99. The firm has a market capitalization of $162.48 million, a price-to-earnings ratio of 6.90 and a beta of 1.10.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the prior year, the company posted $0.12 earnings per share.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the completion of the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $29,726.55. Following the sale, the insider now directly owns 108,951 shares of the company's stock, valued at approximately $343,195.65. The trade was a 7.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 23.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Puma Biotechnology

Hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in Puma Biotechnology during the third quarter worth approximately $34,000. Franklin Resources Inc. acquired a new position in shares of Puma Biotechnology in the third quarter valued at about $41,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Puma Biotechnology in the third quarter valued at about $44,000. Patriot Financial Group Insurance Agency LLC increased its position in Puma Biotechnology by 72.7% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company's stock worth $48,000 after acquiring an additional 8,000 shares during the period. Finally, Royce & Associates LP boosted its holdings in Puma Biotechnology by 71.8% in the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 8,427 shares during the period. Institutional investors own 61.29% of the company's stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.